Some good work there.
There are lots of assumptions, though. What probably do you give those numbers? Are peak revenue numbers really a good way to value a drug during phase 1a and 1b of a trial? Biotech peers dont seem to be able to achieve that.
Like the thought process, though.
Some good work there. There are lots of assumptions, though....
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
-0.015(0.91%) |
Mkt cap ! $281.1M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.66 | $1.64 | $54.86K | 33.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17732 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 2600 | 1 |
View Market Depth
| Last trade - 12.44pm 29/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |